garenoxacin has been researched along with Bacterial Pneumonia in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mikamo, H; Mitsuyama, J; Nakagawa, S; Nomura, N; Shibata, T; Yamagishi, Y | 1 |
Fujita, J; Higa, F; Hiramatsu, K; Kadota, J; Kohno, S; Tateyama, M; Tokimatsu, I; Yamamoto, Y; Yanagihara, K | 1 |
Hosono, H; Ishida, T; Izumikawa, K; Kohno, S; Kushimoto, S; Miyashita, N; Watanabe, A | 2 |
Kobayashi, H; Takagi, H; Tanaka, K; Tsuda, H | 1 |
Fujii, T; Gonoi, T; Imai, K; Iwamoto, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Nakamura, H; Yazawa, K | 1 |
Fukuda, Y; Futakuchi, N; Mitsuyama, J; Nomura, N; Shiokawa, Y; Sugiura, Y; Takahata, M | 1 |
Hammerschlag, MR; Reznik, T; Roblin, PM | 1 |
Fritsche, TR; Jones, RN; Sader, HS; Stilwell, MG | 1 |
1 review(s) available for garenoxacin and Bacterial Pneumonia
Article | Year |
---|---|
Clinical studies of garenoxacin.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Clinical Trials, Phase III as Topic; Fluoroquinolones; Humans; Pneumonia, Bacterial | 2008 |
1 trial(s) available for garenoxacin and Bacterial Pneumonia
Article | Year |
---|---|
Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Injections, Intravenous; Japan; Male; Middle Aged; Pneumonia, Bacterial; Recurrence; Sulbactam; Treatment Outcome | 2013 |
7 other study(ies) available for garenoxacin and Bacterial Pneumonia
Article | Year |
---|---|
Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Area Under Curve; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae | 2017 |
Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan.
Topics: Adult; Anti-Bacterial Agents; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Tablets | 2014 |
Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Pneumococcal Infections; Pneumonia, Bacterial; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Streptococcus pneumoniae; Tablets | 2014 |
Pulmonary nocardiosis caused by Nocardia exalbida complicating Pneumocystis pneumonia in an HIV-infected patient.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Fluoroquinolones; Humans; Male; Middle Aged; Nocardia; Nocardia Infections; Pentamidine; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Sputum; Thienamycins; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
In vitro and in vivo antibacterial activities of garenoxacin against group G Streptococcus dysgalactiae subsp. equisimilis.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Fluoroquinolones; Humans; Male; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Streptococcal Infections; Streptococcus; Treatment Outcome | 2011 |
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
Topics: Adult; Anti-Infective Agents; Canada; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Fluoroquinolones; Humans; Indoles; Japan; Microbial Sensitivity Tests; Pneumonia, Bacterial; Quinolones; United States | 2003 |
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Hospitalization; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2007 |